SUSTAINED RELEASE DELIVERY OF ACTIVE AGENTS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION
First Claim
1. A method to reduce intraocular pressure in an eye of a patient in need thereof, the method comprising administering to the eye of the patient a sustained release topical formulation comprising an intraocular pressure-reducing therapeutic agent, wherein the intraocular pressure-reducing therapeutic agent is capable of being continuously released over time to the eye and wherein the intraocular pressure is reduced at least 10% from baseline.
4 Assignments
0 Petitions
Accused Products
Abstract
The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).
158 Citations
27 Claims
- 1. A method to reduce intraocular pressure in an eye of a patient in need thereof, the method comprising administering to the eye of the patient a sustained release topical formulation comprising an intraocular pressure-reducing therapeutic agent, wherein the intraocular pressure-reducing therapeutic agent is capable of being continuously released over time to the eye and wherein the intraocular pressure is reduced at least 10% from baseline.
- 20. A method to reduce intraocular pressure in an eye of a patient in need thereof, comprising inserting an implant into at least one punctum of the eye wherein the implant comprises a sustained release core comprising an intraocular pressure-reducing agent, wherein the intraocular pressure-reducing therapeutic agent is capable of being continuously released over time to the eye, and wherein the intraocular pressure is reduced at least about 10% from baseline.
Specification